Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies

Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation

(2021) Rémy Duléry et al.   JACC: CardioOncology

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era

(2021) Jason Yeh et al.   Blood Advances

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

(2020) Irwin Walker et al.   Lancet Haematology

Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide

(2020) Jonathan A. Webster et al.   Blood Advances

Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials

(2018) Marcelo C. Pasquini et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti–T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease–Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation

(2017) Robert J. Soiffer et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial

(2017) Jürgen Finke et al.   Lancet Haematology

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease

(2016) Nicolaus Kröger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation

(2016) Stephanie J. Lee et al.   JAMA Oncology

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

(2014) C. G. Kanakry et al.   BLOOD

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

(2014) P. Armand et al.   BLOOD

Comparative Outcomes of Donor Graft CD34+Selection and Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis for Patients With Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transplantation

(2012) Marcelo C. Pasquini et al.   JOURNAL OF CLINICAL ONCOLOGY

Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors

(2012) Claudio Anasetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell–Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous Leukemia in First Remission: Results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303

(2011) Steven M. Devine et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Characteristics of CliniMACS® System CD34-Enriched T Cell-Depleted Grafts in a Multicenter Trial for Acute Myeloid Leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303

(2011) Carolyn A. Keever-Taylor et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

(2010) L. Luznik et al.   BLOOD

High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation

(2010) Leo Luznik et al.   IMMUNOLOGIC RESEARCH

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

(2009) Jürgen Finke et al.   LANCET ONCOLOGY

HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

(2008) Leo Luznik et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION